The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Open accessAbstract
Objective: Epilepsy is a major manifestation of tuberous sclerosis complex (TSC). Everolimus is an mammalian target of rapamycin complex 1 inhibitor with demonstrated benefit in several aspects of TSC. We report the first prospective human clinical trial to directly assess whether everolimus will also benefit epilepsy in TSC patients. Methods: The effect of everolimus on seizure control was assessed using a prospective, multicenter, open‐label, phase I/II clinical trial. Patients ≥2 years of age with confirmed diagnosis of TSC and medically refractory epilepsy were treated for a total of 12 weeks. The primary endpoint was percentage of patients with a ≥50% reduction in seizure frequency over a 4‐week period before and after treatment. Secondary endpoints assessed impact on electroencephalography (EEG), behavior, and quality of life. Results: Twenty‐three patients were enrolled, and 20 patients were treated with everolimus. Seizure frequency was reduced by ≥50% in 12 of 20 subjects. Overall, seizures were reduced in 17 of the 20 by a median reduction of 73% ( p < 0.001). Seizure frequency was also reduced during 23‐hour EEG monitoring ( p = 0.007). Significant reductions in seizure duration and improvement in parent‐reported behavior and quality of life were also observed. There were 83 reported adverse events that were thought to be treatment‐related, all of which were mild or moderate in severity. Interpretation: Seizure control improved in the majority of TSC patients with medically refractory epilepsy following treatment with everolimus. Everolimus demonstrated additional benefits on behavior and quality of life. Treatment was safe and well tolerated. Everolimus may be a therapeutic option for refractory epilepsy in this population. Ann Neurol 2013;74:679–687
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Self-citationThe TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · cited 1×
“TSC1 and TSC2 form a complex responsible for the regulation of the mammalian target of rapamycin complex 1 (mTORC1) via the intermediary signaling protein Rheb (ras homolog enriched in brain).(7) Pharmacologic inhibitors of mTORC1, particularly sirolimus and everolimus, have demonstrated efficacy for the treatment of…”
BackgroundEfficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic Criteria
Roach, E. S., Gomez, M. R., & Northrup, H. (1998) · Journal of Child Neurology · doi:10.1177/088307389801301206 · Cited by 1,081
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001671 · Cited by 1,006
Self-citationReversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882
Bissler, J. J., Kingswood, J. C., Radzikowska, E., Zonnenberg, B. A., Frost, M., Belousova, E., Sauter, M., Nonomura, N., Brakemeier, S., de Vries, P. J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61767-x · Cited by 880
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794
Self-citationDe novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
Lee, J. H., Huynh, M., Silhavy, J. L., Kim, S., Dixon-Salazar, T., Heiberg, A., Scott, E., Bafna, V., Hill, K. J., Collazo, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2329 · Cited by 703
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng, L., Xu, L., Gutmann, D. H., & Wong, M. (2008) · Annals of Neurology · doi:10.1002/ana.21331 · Cited by 639
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 614
Self-citationZeng, L.-H., Rensing, N. R., & Wong, M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0066-09.2009 · Cited by 523
Meikle, L., Pollizzi, K., Egnor, A., Kramvis, I., Lane, H., Sahin, M., & Kwiatkowski, D. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0955-08.2008 · Cited by 501
Meikle, L., Talos, D. M., Onda, H., Pollizzi, K., Rotenberg, A., Sahin, M., Jensen, F. E., & Kwiatkowski, D. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5540-06.2007 · Cited by 462
The Nisonger CBRF: A child behavior rating form for children with developmental disabilities
Aman, M. (1996) · Research in Developmental Disabilities · doi:10.1016/0891-4222(95)00039-9 · Cited by 360
Jóźwiak, S., Kotulska, K., Domańska-Pakieła, D., Łojszczyk, B., Syczewska, M., Chmielewski, D., Dunin-Wąsowicz, D., Kmieć, T., Szymkiewicz-Dangel, J., Kornacka, M., et al. (2011) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2011.03.010 · Cited by 310
Prevalence of tuberous sclerosis estimated by capture-recapture analysis
O'Callaghan, F. J., Shiell, A. W., Osborne, J. P., & Martyn, C. N. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78872-3 · Cited by 287
Chan, J. A., Zhang, H., Roberts, P. S., Jozwiak, S., Wieslawa, G., Lewin-Kowalik, J., Kotulska, K., & Kwiatkowski, D. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.12.1236 · Cited by 258
Behavioral and Cognitive Aspects of Tuberous Sclerosis Complex
Prather, P., & de Vries, P. J. (2004) · Journal of Child Neurology · doi:10.1177/08830738040190090601 · Cited by 235
mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo
Kwon, C.-H., Zhu, X., Zhang, J., & Baker, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2132711100 · Cited by 235
Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy
Huang, X., Zhang, H., Yang, J., Wu, J., McMahon, J., Lin, Y., Cao, Z., Gruenthal, M., & Huang, Y. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.024 · Cited by 231
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
Krueger, D. A., Care, M. M., Agricola, K., Tudor, C., Mays, M., & Franz, D. N. (2013) · Neurology · doi:10.1212/wnl.0b013e3182815428 · Cited by 210
Self-citationTuberous sclerosis complex: a review of neurological aspects
CURATOLO, P., VERDECCHIA, M., & BOMBARDIERI, R. (2002) · European Journal of Paediatric Neurology · doi:10.1053/ejpn.2001.0538 · Cited by 206
Wong, M. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02341.x · Cited by 205
Guo, D., Zeng, L., Brody, D. L., & Wong, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064078 · Cited by 196
Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia
Ljungberg, M. C., Sunnen, C. N., Lugo, J. N., Anderson, A. E., & D’Arcangelo, G. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002386 · Cited by 184
Self-citationActivation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia
Ljungberg, M. C., Bhattacharjee, M. B., Lu, Y., Armstrong, D. L., Yoshor, D., Swann, J. W., Sheldon, M., & D’Arcangelo, G. (2006) · Annals of Neurology · doi:10.1002/ana.20949 · Cited by 160
Recent advances in neurobiology of Tuberous Sclerosis Complex
Napolioni, V., Moavero, R., & Curatolo, P. (2008) · Brain and Development · doi:10.1016/j.braindev.2008.09.013 · Cited by 147
Validation of the Quality of Life in Childhood Epilepsy Questionnaire in American epilepsy patients
Sabaz, M., Lawson, J. A., Cairns, D. R., Duchowny, M. S., Resnick, T. J., Dean, P. M., & Bye, A. M. E. (2003) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.08.012 · Cited by 136
Sunnen, C. N., Brewster, A. L., Lugo, J. N., Vanegas, F., Turcios, E., Mukhi, S., Parghi, D., D’Arcangelo, G., & Anderson, A. E. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03280.x · Cited by 124
Self-citationRapamycin Prevents Seizures After Depletion of STRADA in a Rare Neurodevelopmental Disorder
Parker, W. E., Orlova, K. A., Parker, W. H., Birnbaum, J. F., Krymskaya, V. P., Goncharov, D. A., Baybis, M., Helfferich, J., Okochi, K., Strauss, K. A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005271 · Cited by 122
Russo, E., Citraro, R., Donato, G., Camastra, C., Iuliano, R., Cuzzocrea, S., Constanti, A., & Sarro, G. D. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.09.019 · Cited by 117
Rapamycin Reduces Seizure Frequency in Tuberous Sclerosis Complex
Muncy, J. L., Butler, I. J., & Koenig, M. K. (2009) · Journal of Child Neurology · doi:10.1177/0883073808324535 · Cited by 112
Kotulska, K., Chmielewski, D., Borkowska, J., Jurkiewicz, E., Kuczyński, D., Kmieć, T., Łojszczyk, B., Dunin-Wąsowicz, D., & Jóźwiak, S. (2013) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2013.03.002 · Cited by 107
Everolimus alters white matter diffusion in tuberous sclerosis complex
Tillema, J., Leach, J. L., Krueger, D. A., & Franz, D. N. (2012) · Neurology · doi:10.1212/wnl.0b013e318247ca8d · Cited by 71
Self-citationSha, L.-Z., Xing, X.-L., Zhang, D., Yao, Y., Dou, W.-C., Jin, L.-R., Wu, L.-W., & Xu, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039152 · Cited by 70
Current Management of Tuberous Sclerosis Complex
Krueger, D. A., & Franz, D. N. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00004 · Cited by 67
Self-citationEpilepsy secondary to tuberous sclerosis: lessons learned and current challenges
Moavero, R., Cerminara, C., & Curatolo, P. (2010) · Child s Nervous System · doi:10.1007/s00381-010-1128-8 · Cited by 52
The Nisonger Child Behavior Rating Form: typical IQ version
Aman, M. G., Leone, S. L., Lecavalier, L., Park, L., Buican, B., & Coury, D. L. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f94ad0 · Cited by 46
Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy
Huang, X., McMahon, J. J., & Huang, Y. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.011 · Cited by 42
Zeng, L. (2009) · Molecular and Cellular Pharmacology · doi:10.4255/mcpharmacol.09.16 · Cited by 39
Neurodevelopmental, Psychiatric and Cognitive Aspects of Tuberous Sclerosis Complex
de Vries, P. J. (2010) · Wiley eBooks · doi:10.1002/9783527630073.ch12 · Cited by 31
Prevalence of tuberous sclerosis in UK
Morrison, P., Shepherd, C., Stewart, F. J., & Nevin, N. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60291-7 · Cited by 27
Malformations of Cortical Development: Molecular Pathogenesis and Experimental Strategies
Crino, P. B. (2004) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-6376-8_13 · Cited by 21
Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex
Agricola, K. D., Tudor, C., Krueger, D. A., & Franz, D. N. (2013) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0b013e3182986146 · Cited by 16
Self-citation
Cited by
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31419-2 · Cited by 764
Self-citationLipton, J. O., & Sahin, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.09.034 · Cited by 736
Neurological and neuropsychiatric aspects of tuberous sclerosis complex
Curatolo, P., Moavero, R., & de Vries, P. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00069-1 · Cited by 600
Lim, J. S., Kim, W.-I., Kang, H.-C., Kim, S. H., Park, A. H., Park, E. K., Cho, Y.-W., Kim, S., Kim, H. M., Kim, J. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3824 · Cited by 518
mTOR complexes in neurodevelopmental and neuropsychiatric disorders
Costa-Mattioli, M., & Monteggia, L. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3546 · Cited by 367
Metadata
- Authors
- Krueger, D. A., Wilfong, A. A., Holland‐Bouley, K., Anderson, A. E., Agricola, K., Tudor, C., Mays, M., Lopez, C. M., Kim, M., & Franz, D. N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2013-09-10
- Volume
- 74
- Issue
- 5
- Pages
- 679-687
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1574898460
- Cited by
- 389
- References
- 46
- FWCI
- 30.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.